Skip to main content
Premium Trial:

Request an Annual Quote

New York Approves Exagen Lupus Test

NEW YORK (GenomeWeb News) – Exagen Diagnostics today said that New York has approved its Avise SLE diagnostic, SLE-Systemic Lupus Erythematosus.

The Albuquerque, NM-based firm said that its Avise SLE brand is now available for lupus and connective tissue disease patients across the US. Exagen, which raised $5.3 million last month, runs its CLIA-certified laboratory in Vista, Calif.

Avise SLE is a blood-based test comprising five biomarkers used for ruling in lupus and ruling out other rheumatic diseases. Exagen also offers Avise SLE+ Connective Tissue, a test for helping in the differential diagnosis of autoimmune diseases.

Together, they provide a 19-marker diagnostic that offers greater sensitivity and specificity than methods based on standard antinuclear antibodies and double stranded DNA, the company said.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.